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Alzheimer’s disease (AD) is a growing global epidemic 
crisis. Currently, 35.6 million people are living with 
dementia worldwide; the number is expected to increase 
to 65.7 million in 2030 and 115.4 million in 2050 [1]. 
Th  ese staggering numbers require the development of 
meaningful interventions that will delay the onset, slow 
the progression or improve the symptoms of patients 
suﬀ   ering from this progressive neurodegenerative dis-
order. Many promising agents show eﬃ   cacy  in  pre-
clinical models of AD and must be tested for eﬃ   cacy in 
double-blind, placebo controlled clinical trials.
More AD clinical trials are conducted in the United 
States (US) than in any other single country, but most 
trials now have a signiﬁ  cant number of international sites 
and there are numerous compelling reasons to consider 
incorporating international sites in AD trials. Most 
clinical trials fail to recruit the necessary numbers of 
patients within the anticipated timeframe [2]. Recruit-
ment must extend globally in order to facilitate patient 
recruitment and enable trials to be completed in accep-
table periods. Th   e presence of large numbers of patients, 
many of whom are treatment naïve, enhances the 
attractive  ness of international clinical trial sites. In 
addition, trials conducted outside of the US are typically 
less expensive, providing another motivation for ex-US 
drug development. Th  ere are an increasing number of 
well trained scientists internationally, and laws and 
regulatory provisions make using foreign sites an attrac-
tive alternative [3]. Finally, most patients with dementia 
live in the developing world [4] and the growing size of 
international pharmaceutical markets [5] attracts spon-
sors to conduct studies in countries where pharma  ceu-
tical sales may be pursued. With the growth of globaliza-
tion of clinical trials, there are now more studies 
conducted collectively outside of the US than within the 
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will continue into the foreseeable future [7].
Th   ere are many challenges to reliable drug development 
in global settings and some of the recent failures in AD 
drug development may be attributable in part to 
inadequate attention to these issues [8]. Here we discuss 
the aspects of drug development to be considered when 
implementing global clinical trials for AD therapies.
Current global distribution of Alzheimer’s disease 
trials
A search of the ClinicalTrials.gov registry using the term 
‘Alzheimer’s’, was reﬁ  ned to ‘trials funded by industry’. 
Th   is search yielded 475 studies as of 3 March 2011. From 
these results, studies were included if they had a status of 
‘recruiting’, ‘active, not recruiting,’ or ‘enrolling by 
invitation’; 269 studies met the inclusion criteria.
Th   e number of locations listed for each study in each of 
14 regions was analyzed. Th   e regions were: US, Canada, 
South America, Mexico/Central America, Middle East, 
Africa, Western Europe, Eastern Europe, Russia, India/
Southeast Asia, China, Korea, Japan and Australia/New 
Zealand. Sites in Taiwan and Hong Kong were included 
with China. Western Europe was deﬁ  ned as the United 
Kingdom, Ireland, Iceland, Portugal, Spain, France, 
Benelux, Denmark, Norway, Sweden, Finland, Germany, 
Austria, Switzerland, and Italy. Th  e group of Eastern 
European countries excluded Russia, which was its own 
region. Turkey was included with the Middle East. Most 
of the trials were for pharmaceutical agents; a few (11) 
are for evolving diagnostic devices or procedures.
Of the 269 studies meeting the search criteria, 76 (28%) 
are being conducted in the US whereas a majority of 
trials are occurring outside the US (Table 1). Western 
Europe is host to 43 studies (16%); other countries each 
had fewer trails but collectively accounted for a majority 
of trials. Forty-nine (18% of all trials; 64% of all US trials) 
are being conducted only in the US; 27 (10% of all trials; 
35% of US trials) are multinational. Th   e US has the largest 
number of trial sites (1,937 total for all sites in all trials; 
many sites participate in several trials and the total 
includes these sites for every trial), contributing 48% of 
all active trial sites for all trials. Europe had the second 
largest number of active trial sites (921; 23%). As in the 
total number of trials, there were more trial sites (52%) 
outside the US than within.
Th  e global distribution of trials by phase is shown in 
Table 2. ClinicalTrials.gov lists 25 phase 1, 49 phase 2, 30 
phase 3, and 15 phase 4 AD trials. Phase 1 trials may be 
under-represented in the data base since some foreign 
phase 1 trials are not conducted under an investigational 
new drug application [7]. Of the phase 1 trials listed, 
most are conducted in the US and Western Europe (20 of 
25 are conducted in these two regions). Phase 2 and 
phase 3 trials are conducted worldwide; most countries 
except Russia have approximately equal numbers of 
phase 2 and 3 trials. Russia has a predominance of phase 
2 AD trials (7 of 11 trials conducted in Russia). Th   e US is 
involved in 52% of the listed phase 1 trials, 59% of phase 2 
trials, and 73% of phase 3 trials.
Aspects to be considered in globalized Alzheimer’s 
disease trials
Th  e International Conference for Harmonization (ICH) 
guideline E5 [9] provides a framework for discussing 
ethnic inﬂ  uences in clinical trials relevant to globalized 
drug development programs. Th   e guidelines divide ethnic 
inﬂ   uences into intrinsic and extrinsic factors. Table  3 
provides a summary of major dimensions of drug 
develop  ment to be considered when planning global AD 
clinical trials.
Host factors that may aff  ect disease progression
Th  e Human Development Index, which consists of life 
expectancy, education and per capita gross national 
income (as an indicator of standard of living), provides 
insight into diﬀ  erences in patient conditions throughout 
the world. Human Development Index scores vary from 0 
(very poor) to 1 (very good). North America and Australia 
generally have values of 0.9 and above; Russia 0.7 to 
0.749; China 0.65 to 0.69; India 0.55 to 0.59; parts of 
Africa may be as low as under 0.3 [10]. Studies of speciﬁ  c 
health indices across countries also provide examples of 
international variability. For example, a comparison of 
cardiovascular health of individuals included in the US 
Table 1. Current global distribution of Alzheimer’s disease 
trials funded by industry
  Total number of 
Regions  locations by region  Total clinical trials
United States  1,937  76
Western Europe  921  43
Canada 171  23
Eastern Europe  238  22
Australia/New Zealand  113  20
Japan 305  17
South America  87  13
Korea 31  12
Russia 91  11
Middle East  48  10
China 27  9
Africa 33  6
Mexico/Central America  19  5
India/Southeast Asia  11  2
Trial sites typically participate in more than one trial and may be represented 
several times in the ‘Total number of locations by region’ column.
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the health measures of those included in the Nutrition 
and Health Survey in Taiwan revealed diﬀ  er  ences 
between the two ethnic groups in left ventri  cular 
hypertrophy, serum lipids, obesity and smoking status 
[11]. Such international diﬀ  erences could translate into 
diﬀ   erences in cerebro  vascular co-morbidity, cogni  tive 
reserve, and adverse event vulnerability. Health status 
measures could be incor  porated in trial analyses to 
address variability introduced by international health 
disparities.
Education levels also vary substantially from country to 
country. Th   e average education level in the US is 12 years; 
Japan has an average education level of 9.5 years; United 
Kingdom 9.4; France 7.9; Italy 7.2; Th  ailand 6.5; China 
6.4; India 5.1; and Brazil 4.9 [12]. Many countries 
included in global clinical trials have less than half the 
educational level of US trial participants. In a validity 
study of the Chinese version of the Alzheimer’s Disease 
Assessment Scale - Cognitive portion (ADAS-cog), for 
instance, 35% of the trial subjects had ﬁ  ve or fewer years 
of education [13]. Th  is contrasts with the US, where 
participants have an average of 14 years of education in 
recent trials [14]. Individuals with lower levels of 
education tend to progress more slowly in the course of 
AD [15]. Persons with higher levels of education progress 
more rapidly, have higher levels of neuritic plaques at 
autopsy, and have more severe abnormalities on ﬂ  uoro-
deoxyglucose positron emission tomography and amyloid 
imaging than those with lower levels of educational 
achievement [16-19]. Placebo groups would decline more 
slowly and larger number of individuals would be 
required to show a drug-placebo diﬀ  erence in a poorly 
educated population compared to a well educated popu-
la tion.  Eﬀ   ects of education on disease progression in 
diﬀ  erent regions have not been investigated, and educa-
tional level should be considered as a potentially 
Table 2. Distribution of Alzheimer’s disease trials by phase
  Phase 1  Phase 2  Phase 3  Phase 4
United Statesa 13  29  22  7
Western Europe  7  17  15  1
Canada 0  10  11  1
Eastern Europe  0  10  11  0
Australia/New Zealand  2  6  10  1
Japan 1  4  9  2
South America  0  5  7  0
Korea 0  3  5  1
Russia 0  7  4  0
Middle East  1  3  3  3
Chinab 1  2  4  1
Africa 0  1  4  0
Mexico/Central America  0  2  3  0
India/Southeast Asia  0  0  1  1
aThe United States had one trial listed as phase I/II. bChina had one trial listed as 
phase II/III.
Table 3. Factors that may eff  ect global Alzheimer’s disease 
clinical trials
    Host factors that may aff  ect disease progression
  General health and standard of care
 Education
Population factors that may aff  ect drug pharmacokinetics
 Body  size
  Polymorphisms of drug metabolizing enzymes
Population factors that may aff  ect Alzheimer’s disease biology
  Genotypes such as apolipoprotein E ε4 allele carrier status
 Head  size
Alzheimer’s disease diagnosis
  Attitudes toward aging
  Expertise in AD diagnosis
  Behavioral manifestations of AD
  Availability of advanced diagnostics, such as neuroimaging
Clinical trial instrumentation
 Translation
 Acculturation
  Perspectives on behavioral changes, such as apathy
Cultural eff  ects on measures such as the diffi   culty of obtaining ADL 
information where domestic help is widely available
Clinical trial conduct
  Experience of investigators
  Patient and caregiver attitudes
  Training of raters 
Institutional review boards and human protection
  Availability of standard AD therapies
Clinical trial data analysis
  Sample size considerations
  Extrapolation of data between countries
 Bridging  studies
Regulatory factors
  Multi-regional development program requirements
  Country-specifi  c development program requirements
Sample handling
  Sample collection and export
  Laboratory standardization procedures
Supply line factors
 Importation  laws
AD, Alzheimer’s disease; ADL, activities of daily living.
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global trials. Th  e level of education in the proposed 
population would need to be known to model the 
magnitude of this eﬀ  ect for speciﬁ  c trials.
Exercise levels may also vary among global populations 
and exercise has been shown to inﬂ  uence amyloid-beta 
protein abnormalities in cognitively normal older persons. 
Individuals with higher levels of exercise have lower 
levels of amyloid on amyloid imaging and higher (less 
abnormal) levels of amyloid levels in the cerebrospinal 
ﬂ   uid [20]. Th  is inﬂ   uence should be considered when 
popu  lations with markedly diﬀ  erent exercise levels are 
included in global prevention trials of agents targeting 
beta-amyloid mechanisms.
Population factors that may infl  uence drug 
pharmacokinetics
Diﬀ  erences in body size would be expected to contribute 
to diﬀ  erences in brain exposure levels when patients of 
diﬀ   erent sizes are given similar doses of drugs. Th  e 
average height in Sweden, for example, is 1.815 meters, 
whereas the average height in the Philippines is 1.634 
meters, a 20 centimeter diﬀ  erence with corresponding 
anticipated diﬀ  erences in drug exposures [21]. In Japan, 
where body size tends to be smaller than in Western 
nations, two-thirds of new molecular entities approved 
between 2003 and 2005 had standard doses that diﬀ  ered 
from those approved in the US and Europe [22].
Obesity likely may aﬀ   ect drug metabolism and 
distribution. Obesity is more common in Western popu-
lations. Lipophilic drugs will have disproportionately 
large volumes of distributions in obese and overweight 
individuals [23]. Such diﬀ  erences may aﬀ  ect brain expo-
sures and both eﬃ   cacy and adverse event occurrence.
Polymorphisms that may inﬂ  uence drug metabolism, 
such as those governing cytochrome P450 enzymes, may 
also vary substantially across ethnic groups and could 
contribute importantly to diﬀ  erences in drug metabolism, 
central nervous system drug exposure, and drug response 
[24,25]. Th   ere are more slow metabolizers in Asian popu-
la  tions, possibly leading to higher exposure levels with 
contrasting eﬃ     cacy and side eﬀ  ect  proﬁ  les  among 
participants in global trials.
Concomitant approved drugs taken by patients in trials 
may also aﬀ  ect trial results through drug-drug and drug-
disease interactions. Diﬀ  erent approaches to managing 
medical conditions prevail globally and average doses in 
clinical use may vary. Japanese physicians, for example, 
tend to use small doses of several medications to manage 
medical illnesses; European doctors tend to gradually 
titrate single medications upward; and US physicians are 
more likely to press the dose upward until toxicity occurs 
and then titrate downward [23]. Th   ese practice patterns 
result in smaller doses of medications in Japan, 
inter  mediate doses in Europe, and higher doses in the 
US. Th  is creates an opportunity for diﬀ  ering drug-drug 
inter  actions across regions.
Some compounds may be less sensitive to ethnic-
related inﬂ  uences and are better candidates for global 
clinical trials. Table 4 summarizes the characteristics of 
compounds less sensitive to ethnic inﬂ  uences.
Biological therapeutic agents may be subject to 
somewhat diﬀ  erent global inﬂ  uences than small molecule 
drugs. Asians, for example, have higher rates of exposure 
to infections and a diﬀ  erent complement of circulating 
antibodies; they are less likely to have been included in 
national immunization campaigns and therefore have 
more naïve immunological backgrounds from an iatro-
genic perspective [23].
Population factors that may aff  ect Alzheimer’s disease 
biology
Genetic diversity also creates diﬀ  erences in the biology of 
AD relevant to clinical trials. Th  e apolipoprotein E ε4 
allele (APOE ε4) varies from a high frequency of 0.221 in 
Oceania to a low frequency of 0.068 in India [26]. APOE 
ε4 carrier status inﬂ  uences the rate of progression of both 
cognitive and functional decline in patients with mild 
cognitive impairment and prodromal AD [27,28]. Ethnic 
diﬀ  erences in receptor sensitivity and pathway modu  la-
tion have been insuﬃ     ciently explored but also could 
aﬀ  ect drug eﬃ   cacy in diverse populations. Th  is  variability 
across ethnicities and regions could inﬂ   uence rate of 
disease progression and aﬀ  ect the sample size needed to 
observe a drug-placebo diﬀ   erence with an eﬃ   cacious 
agent.
Head size and brain size reﬂ  ect cognitive reserve and 
have an important interaction with disease state. Head 
size reﬂ   ects brain size and neuronal number. Smaller 
head size has been associated with more rapid progres-
sion of AD [29]. Similarly, smaller head size is associated 
Table 4. Characteristics of compounds less sensitive to 
ethnic infl  uences and better candidates for global trials
Linear pharmacokinetics
Wide therapeutic dose range
Minimal metabolism or not metabolized by enzymes subject to genetic 
infl  uences
High bioavailability
Little inter-subject variability in bioavailability
Low protein binding
Limited potential for drug-diet interactions
Limited potential for drug-drug interactions
Limited potential for abuse or inappropriate use
Not a prodrug
Adapted from [1,3,23].
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to persons with larger heads [30]. Persons with smaller 
body size have correspondingly smaller head sizes and 
patients from countries with smaller citizens might 
progress more rapidly in trials. More comprehensive 
modeling of this eﬀ   ect is needed and collection of 
empirical data is warranted.
Diet and nutrition might also contribute to diﬀ  erences 
in therapeutic response, side eﬀ   ect vulnerability, and 
disease progression. Populations with high levels of 
antioxidants in the diet might reduce oxidative injury, 
while those with high levels of salt or animal fats may be 
more vulnerable to hypertension, cardiovascular disease 
and central nervous system co-morbidity.
Approaches to Alzheimer’s disease diagnosis that may 
diff  er among countries
Attitudes toward aging dictate the extent to which cogni-
tive decline is considered abnormal and may aﬀ  ect rates 
of referral for evaluation and trial participation. Asian 
countries place less emphasis on the importance of 
memory in aging, and AD is less likely to be perceived as 
an abnormality [4]. In countries where aging and 
dementia are not distinguished, referral for cognitive 
assessment is typically later in the disease course when 
cognitive decline is more severe; consultation may be 
triggered by behavioral changes rather then cognitive or 
memory complaints [4,31]. Dementia diagnosis will be 
delayed in these settings and behavioral disturbances are 
more common in conjunction with AD diagnoses.
In some countries, the high frequency of hypertension, 
cardiovascular, and cerebrovascular disease will increase 
the proportion of patients with mixed dementia syn-
dromes or comorbid central nervous system pathology 
[32].
Clinical phenomenology may be aﬀ   ected by inter-
national setting. For example, rates of apathy as measured 
by the Neuropsychiatric Inventory (NPI) are lower in 
Asian compared to US populations [33], likely attribu-
table to diﬀ  erences in expectations of activity levels and 
the value placed on serenity in elderly persons.
Clinicians vary widely in the extent to which they use 
standardized rating scales and collect systematic infor-
mation on AD in their clinical practices [34]. Diﬀ  erences 
in practice may translate into diﬀ   erences in under-
standing the variability in presentations of AD and their 
impact on diagnosis.
Aspects of clinical trial instrumentation that may aff  ect 
trial outcomes
Nearly all widely used clinical trial instruments for AD 
were developed in North America, and they may not be 
well suited for use in other countries, especially those 
with diﬀ   erent cultural heritages. Using the same 
instru  ments in all sites of a global clinical trial is required 
for data uniformity and analysis, but the quality of the 
data collected may be aﬀ  ected by diﬀ  ering cultural and 
national inﬂ  uences. Elderly in many developing countries 
have low levels of reading and health literacy, poor test-
taking skills, and higher levels of test-related anxiety [4]. 
If skills improve and anxiety declines with multiple test 
sessions, both the active treatment group and the placebo 
group will exhibit substantial improvement, possibly 
obscuring a drug-placebo diﬀ  erence.
Th   ere have been numerous local translations of clinical 
trial instruments, often with little attempt at harmoni-
zation or consideration of the impact of the diﬀ  erences 
on trial outcomes. In the Hindi version of the Mini-
Mental Status Examination, for example, 16 of the items 
were changed to make it culturally appropriate [4]. Even 
within the US, substantial administration and scoring 
variances have been documented for the ADAS-cog [35] 
and the NPI [36]. Th  ese diﬀ  erences are exaggerated in 
global trials.
Normative data for trial instruments are often lacking 
in cultures where clinical trials are conducted and cutoﬀ   
scores for study entry as well as expected performances 
for healthy elderly persons may be diﬃ   cult to extrapolate 
from Western experience. Th   is can result in entry of non-
compromised patients into prodromal AD and AD 
dementia trials because of culturally and educationally 
appropriate low scores.
Trial data for the Clinical Dementia Rating (CDR), 
Activities of Daily Living Scale, and the NPI are collected 
from caregivers. Th   e role of the care partner may be more 
straightforward in Western countries than in many 
developing nations. Patients tend to live at home in ex-
tended families with multiple caregivers. Many families, 
even those of modest ﬁ  nancial means, employ domestic 
maids who may speak diﬀ  erent dialects or even diﬀ  erent 
languages from the patients [4]. Th  ese indivi  duals are 
responsible for the majority of the daily care of the 
aﬀ  ected person. How best to collect information under 
these circumstances and how best to deﬁ  ne ‘caregiver’ 
can be challenging. Many indigenous persons have 
extremely simple life styles unencumbered by utilities and 
conveniences; the usual trial instruments will not eﬀ  ec-
tively quantify functional changes in these circumstances.
Biological measures may also be diﬀ  erentially 
acceptable across international trial sites. Asian patients 
are reported to be more reluctant to undergo invasive 
procedures and less likely to participate in trials including 
lumbar puncture [4].
Clinical trial conduct practices that may vary among 
countries
Clinicians and trial sites vary widely with regard to their 
experience in conducting AD clinical trials. In a review of 
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training company found that 57% of raters had more than 
5 years’ experience in administering the ADAS-cog and 
27% had less than 1 year’s experience [37]. Among raters 
in China included in a recent trial, 40% of raters had 
administered the ADAS-cog fewer than ﬁ  ve times. Lack 
of experience can lead to greater score variability and 
more diﬃ   culty demonstrating a drug-placebo diﬀ  erence 
of an eﬀ  ective compound.
Clinical trial conduct includes training the sites on how 
to administer the assessment instruments and monitor-
ing sites for appropriateness of trial data collection. Many 
investigator meetings focus on proper scoring of instru-
ments based on videotaped interviews by experts. 
Investi  gators and research assistants may have limited 
opportunity to administer the examinations under super-
vised circumstances. Reliability studies of the Clinical 
Dementia Rating show that at least ﬁ  ve administrations 
of the tool at each severity level are required to achieve 
inter-rater reliability [38]. Trial investigators are not trained 
to this level of reliability, and data collected exhibit large 
standard deviations and conﬁ  dence intervals.
Studies have also shown substantial variability in trial-
to-trial instructions for both the ADAS-cog [35] and the 
NPI [36]. Th   is variability causes uncertainty among trial 
site personnel as they encounter the same scale adminis-
tered in diﬀ  erent ways by varying sponsors. Th  is  increases 
score variability and undermines the ability to demon-
strate a drug-placebo diﬀ  erence of eﬀ  ective agents.
Once trained, raters may not continue to rigorously 
adhere to scoring conventions and administration 
standards. In one international study with a ratings 
surveillance program in place, half of ADAS-cog raters 
and one-third of Mini-Mental Status Examination raters 
required some level of remediation after the conclusion 
of rater training [37]. Such programs are not in place for 
all trials and rater drift may aﬀ  ect outcomes.
Th   ese studies demonstrate deﬁ  ciencies in training and 
test application in trials. Th   ese problems are not unique 
to international trials but are ampliﬁ  ed in global trials 
where diﬀ  erences in language and trial site experience 
may be more marked and further undermine data relia-
bility. Greater attention to rater training and rater moni-
tor  ing or use of centralized raters may assist in manag  ing 
measurement-related variability in AD clinical trials.
Good Clinical Practice guidelines have been incorpor-
ated into trial procedures to a variable extent across 
international sites. Th  is leads to variations in the care 
with which informed consent is obtained, diligence in 
application of inclusion and exclusion criteria, rigor of 
collecting information on concomitant medications and 
use of over-the-counter treatments, attention to time-
frames of data collection, thoroughness of adverse event 
reporting, and completeness of data collection and 
recording [37]. Th   is variable familiarity with and applica-
tion of good clinical practice may aﬀ  ect data quality.
Protection of human subjects and obtaining informed 
consent through provision of complete information to 
patients and caregivers and insuring that they understand 
the procedures, risks, and expectations of clinical trial 
participation is an essential and required aspect of AD 
clinical trial conduct. In countries with less extensive 
histories of research conduct and investigations involving 
human subjects, there may be less familiarity with these 
procedures. Institutional review boards may be inexperi-
enced and understaﬀ  ed [37,39]. Th   is exposes the study to 
uninformed patient participation, lack of protection of 
human rights, unacknowledged conﬂ  icts of interest, and 
violations that may compromise study validity and 
acceptability.
Pharmacovigilance, both during trials and after drug 
approval in any country, provides critical data on drug 
safety and mechanisms must be in place to share this 
information globally in a timely way with appropriate 
translations and mechanisms for notifying local insti  tu-
tional review boards and patients.
Extrapolation of clinical trial data among regions
Guidelines regarding the proper sample size and statis-
tical approaches to multi-regional trials are evolving. 
ICH guidelines [4] provide general instructions regarding 
extrapolation of data between regions and when bridging 
studies will be required. Tsou and colleagues [40] suggest 
that consistency of responses across ethnic groups in 
global trials is an important means of determining if 
responses can be extrapolated across regions. Ethnic 
groups or nations must comprise at least 20% of the trial 
population to make such analyses feasible [40]. Consis-
tency in analyses can also be applied to determine if trials 
conducted in speciﬁ  c regions have outcomes consistent 
with reference trials conducted for regulatory approval in 
other countries [41].
Bridging studies are required by regulatory bodies 
when the validity of extrapolation of data from one 
region to another is uncertain. Bridging studies can vary 
from demonstration of safety in the new region, to dose-
response pharmacokinetic studies, to comprehensive 
clinical trials with requirements to demonstrate treat-
ment eﬃ     cacy [42,43]. Drugs less sensitive to ethnic 
factors (Table 4) are less likely to require bridging studies. 
Bridging studies can be conducted simultaneously with 
pivotal trials in global drug development programs to 
reduce delay in seeking marketing authorization in 
several countries at study conclusion [42].
Regulatory factors that may vary among countries
Th   e ICH guideline E5 provides a framework for con  sider-
ing ethnic inﬂ   uences in global clinical trials [9]. Th  e 
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duplication of trials, save human and material resources, 
and expedite the development of medications to beneﬁ  t 
patients [44]. Th  is guidance is the major regulatory 
reference for sponsors and contract research organiza-
tions conducting international clinical trials.
For industry sponsors pursuing marketing authoriza  tion 
in international markets, strategies and requirements 
diﬀ  er by country. Japan generally requires that 50 to 60% of 
patients in a trial be Japanese for the agent to be considered 
for regulatory approval there. China requires that 200 to 
300 Chinese patients be included in a trial [23].
Th   e US Food and Drug Administration (FDA) accepts 
foreign data in support of a marketing application for a 
human drug, biological product, or device as long as the 
data were collected in a study conforming to the ethical 
principles contained in the Declaration of Helsinki [45]. 
It is anticipated that the number of US patients in a 
pivotal trial comprising part of a New Drug Application 
(NDA) will permit analysis to determine if the agent was 
eﬀ  ective in the US population.
Data from international trial sites are increasingly 
included in marketing applications for drugs and 
biologics. In 2008, 80% of applications included at least 
some data from foreign clinical trials [2]. Th   e rise in the 
number of trials conducted abroad has not been matched 
with FDA regulatory scrutiny. An Oﬃ   ce of the Inspector 
General review found that the FDA conducted inspec-
tions on only 0.7% of foreign clinical trial sites [46]. Th  e 
results of these reviews suggested that international sites 
often do not meet expected clinical trial conduct criteria.
Clinical operations and sample handling that may aff  ect 
global trials
Contractual relationships may vary from country to 
country and operational ﬂ  exibility is required for global 
clinical trials. Administrative and ﬁ  nancial arrangements 
also diﬀ  er among countries.
Biomarker capacity may vary markedly among global 
sites. Th  e US, Canada, and Western Europe tend to be 
early adopters of new technology compared to other 
countries, and advanced imaging capability will typically 
not be as widely available as clinical expertise in global 
sites. Use of phantoms for image standardization and 
machine calibration may not be familiar to all sites, and 
sponsors of international trials will need to provide 
additional technical expertise to ensure quality [47]. Use 
of centralized reading of brain imaging is advantageous 
to minimize site-to-site variability in image interpretation.
Sample collection and handling may also pose challenges 
in global trials. China, for example, has restrictions on 
DNA and plasma export, requiring identiﬁ  cation  and 
standardization of a reference laboratory in China in 
order to pursue trials in that country.
Maintaining supply line integrity can be diﬃ   cult  in 
international circumstances. Importation laws can slow 
movement of drugs across international borders and 
implementing Good Manufacturing Practices for local 
production can take valuable time and delay trial 
initiation.
Comment
Globalization of AD clinical trials is a consistent trend 
over the past decade and will continue into the fore  see-
able future [7]. Including international sites in AD trials 
allows timely patient recruitment, diversiﬁ  cation of trial 
participants (including patients more likely to be 
treatment naïve), conduct of trials with less expense and 
facilitation of marketing applications in participating 
countries. Global trials have advantages for patients, 
investigators, and sponsors. Patients get access to experi-
mental agents and may experience a higher level of care 
than is otherwise available; medications may become 
available in international markets more rapidly. Investiga-
tors are able to participate in international collaborations, 
contribute to the advancement of therapies and scientiﬁ  c 
progress, increase skill levels of themselves and their 
teams, may augment income and may experience 
increased prestige and credibility. Sponsors beneﬁ  t from 
cost savings, speed of recruitment, and market access. 
Th  ese advantages must be considered in the context of 
the many challenges to conducting clinical trials on a 
global scale, including uncertainties regarding diﬀ  erences 
in disease biology, the eﬀ  ect of ethnicity on drug pharma-
cokinetics and pharmacodynamics, and challenges to 
adequate human protections.
Attention to the factors discussed (Table 3) is necessary 
to ensure the integrity of data included in multiregional 
trials. Many issues that may aﬀ  ect global trials have not 
been studied in suﬃ   cient detail to predict the magnitude 
of the eﬀ  ect on trial outcomes. Some issues such as trial 
conduct can be addressed by rigorous site training and 
scrupulous monitoring and oversight during the course 
of the trial. Central ratings and application of new assess-
ment technologies, such as computerized data collection, 
may improve some aspects of data quality. Biological 
factors that may be related to ethnicity and may aﬀ  ect 
pharmacokinetics, pharmacodynamics, and disease bio-
logy are more diﬃ     cult to address. More rigorous 
scientiﬁ  c investigation of these factors and their eﬀ  ects in 
trials is needed. Complex modeling may be needed to 
determine the eﬀ   ects of education and head size on 
disease progression, for example; such models may 
determine adjustments in sample size or trial duration 
needed for eﬃ   cacy trials.
Scrutiny of the factors aﬀ  ecting international trials will 
help avoid failed trials and facilitate the development of 
urgently needed new treatments for AD.
Cummings et al. Alzheimer’s Research & Therapy 2011, 3:24 
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Intrinsic biological and extrinsic sociocultural factors 
may aﬀ  ect trial outcomes in AD drug development pro-
grams. Host, disease and trial conduct practices may all 
vary internationally. Cross-national comparison studies 
are few and the eﬀ  ect of regional variations has been 
inadequately explored. Attention to these factors is 
important to successful global trials.
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